Read the quarter in context.
A source-linked quarter view: reported numbers, management language, guidance, and the risks that should carry forward.
ConCallIQ research layer
Signal, with the source still visible.
Use the controls below to narrow the view, then follow the evidence into the next layer of context.
Revenue
Pending
verification pending
Revenue YoY
—
reported change
EBITDA
Pending
latest reported figure
Source
bse pending
record provenance
Actual signal trajectory
Where this quarter sits.
Quarter read
What the record says.
SBI Life reported a strong Q4 FY25 with PAT up 27% to INR 24.13 billion, driven by improved product mix and margin expansion. Individual new business premium grew 11% to INR 263.6 billion, with private market share at 25.3%. VNB margin improved to 30.5% in Q4 (up 220 bps YoY) due to a shift toward traditional products. Management guided for 13-14% individual APE growth in FY26, with agency channel expected to grow ~25% and bancassurance ~10%. Product mix is targeted to shift from 70/30 to 65/35 (ULIP/traditional). Key risks include potential regulatory changes on bancassurance and equity market volatility impacting ULIP demand.
Colored figures show movement against the previous available record.
Guidance to track
- Management expects individual APE to grow 13-14% in FY26, slightly above industry growth of ~12%.
- Agency channel is expected to grow around 25% on a strong base, driven by agent additions and productivity improvements.
- Management targets shifting product mix from 70/30 to 65/35 (ULIP/traditional) in FY26, with a 500 bps tilt toward traditional products.
- Management expects VNB margin to remain around 27-28% for FY26, despite product mix improvement, due to investments in infrastructure.
Risks flagged
- Potential regulatory restrictions on bancassurance could impact a key distribution channel, though no formal discussions have occurred yet.
- ULIP degrowth in Q4 was attributed to equity market volatility; continued weakness could affect growth and product mix targets.
- 49-month persistency (COVID cohort) showed weakness, though management has taken revival measures and expects improvement.
- OpEx ratio increased from 4.9% to 5.3% due to branch expansion and hiring; further investments may pressure margins.
Key quotes
- We have doubled our VNB in the last four years.
- Going forward, what we are looking for is a 65/35 kind of product mix.
- Our mis-selling ratio stands at 0.02%, which is one of the lowest in the industry.
Research modules